Global Kidney Cancer Drugs Market is expected to reach US$ 6,441.9 Mn by 2025: Credence Research

According to the latest market report published by Credence Research, Inc. “Kidney Cancer Drugs/Renal Cell Carcinoma (RCC) Market - Growth, Future Prospects, and Competitive Analysis, 2017 - 2025,”

ID: 1531813
recent pressrelease next pressrelease

(businesspress24) - According to the latest market report published by Credence Research, Inc.8.1% from 2017 to 2025

Browse the full

Market Insights

Kidney cancer/ renal cell carcinoma (RCC) is among ten most commonly observed cancer these days. It is sixth common cancer observed in men and it is the tenth most common cause of cancer for women. According to American Cancer Society study in U.S. around 63,990 adults (40,610 men and 23,380 women) new cases of kidney cancer will be diagnosed. The average age of diagnosis is 64 and is rarely found in people under 45. It is estimated that 65% of people are diagnosed when the cancer is only located in the kidney and the 5-year survival rate is 93% in this group. The incidence of renal cell cancer is observed highest in Northern America and Europe. Almost 59%of kidney cancer cases is observed in developed countries. Thus, rising incidence of kidney cancer and entry of novel drug treatment are the key factors contributing to the growth of kidney cancer drug market.

The global kidney cancer drugs market is segmented by drugs type into Sutent (Sunitinib), Nexavar (Sorafenib), Afinitor (Everolimus), Votrient (Pazopanib), Inlyta (Axitinib), Avastin (Bevacizumab), Torisel (Temsirolimus) and Proleukin (Aldesleukin). Sutent dominates the global kidney cancer/renal cell carcinoma drugs market.

As of the current market scenario, North America dominates the global kidney cancer drugs market followed by the Europe. Rise in incidence of renal cancer, increasing geriatric population and novel drug treatment are key drivers for the growth of kidney cancer drug market in North America. Asia Pacific is the fastest growing regional market for kidney cancer drugs with highest CAGR in the forecast period. With improvement in diagnostic technology, rise in aged population and low cost production of drugs are some of the key factors contributing to the growth of Asia Pacific region.

Market Competition Assessment:

Key players in the global kidney cancer drugs market are Active Biotech Ab, Amgen, Bayer AG, Cipla Limited, F. Hoffmann-La Roche Ag, Genentech, Inc., Glaxosmithkline Plc, Novartis AG, Onyx, Pfizer, Inc. and others.

Browse the full

Key Market Movements:

Kidney cancer is the most common cancer observed falling within top ten most common cancer in both male and female. Rising incidence of kidney cancer due to adoption of unhealthy life style such as smoking, drinking and less physical activity. Thus increase in aged population and incidence of kidney cancer would propel the growth of kidney cancer drugs market.
Further approval of novel drugs would fuel the growth of global kidney cancer drugs market
Table of Content

Chapter 1. Preface
1.1. Report Scope and Description
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase II-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted

Chapter 2. Executive Summary
2.1. Global Kidney Cancer Drugs Market Portraiture
2.1.1. Global Kidney Cancer Drugs Market, by Drug Type, 2016
2.1.2. Global Kidney Cancer Drugs Market, by Geography, 2016

Chapter 3. Kidney Cancer Drugs: Market Dynamics and Future Outlook
3.1. Market Overview
3.2. Epidemiology of Kidney Cancer
3.3. Drivers
3.4. Challenges
3.5. Opportunities
3.5.1. Attractive Investment Proposition, by Geography
3.6. Competitive Landscape
3.6.1. Competitive Landscape, by Key Players, 2016.............

Visit Our Blog at

Company Profiles

About Us:

Credence Research


Name: Chris Smith

Designation: Global Sales Manager

E-mail: sales(at)

Ph: 1-800-361-8290


More information:

Keywords (optional):

Company information / Profile:

PressRelease by


PressContact / Agency:

published by: David23
print pressrelease  send to a friend  

Date: 01/24/2018 - 05:46
Language: English
News-ID 1531813
Character count: 5327
Firma: Credence Research
Ansprechpartner: David Colin Feedback to about Pressrelease-id:
Stadt: San Jose
Telefon: 18003618290

Meldungsart: bitte
Versandart: Veröffentlichung

Number of hits: 278


Direct Link to this PressRelease:

We would appreciate a link in your News-, Press- or Partner-Site.

Comments on this PressRelease

All members: 9 024
Register today: 0
Register yesterday: 3
Members online: 0
Guests online: 82

Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.